Literature DB >> 7501785

Psychiatric symptoms in progressive supranuclear palsy.

M A Menza1, J Cocchiola, L I Golbe.   

Abstract

Progressive supranuclear palsy (PSP) is an unusual neurodegenerative disorder that superficially resembles Parkinson's disease (PD). It is characterized by gaze palsy, bulbar signs, parkinsonian signs, and mental changes. While mental changes are a frequent finding, they have, with the exception of dementia, been poorly defined. In this study, 19 patients with PSP were evaluated psychiatrically and compared with 42 patients with PD. Fifty-two percent of the patients had some degree of dementia, as measured by the Mini-Mental State Exam. Eight (42%) of the PSP patients had other psychiatric diagnoses, mostly relatively mild depression or anxiety, though two patients had more severe depression. Six (32%) patients had pathologic laughing or crying, and four of these had a psychiatric diagnosis other than dementia. The PSP patients did not differ from the PD patients on measures of depression or anxiety and did not have a greater rate of formal psychiatric diagnoses. This study confirms previous reports of dementia as a common feature of PSP. It further suggests that psychiatric disturbances, while common, are generally relatively mild, though more serious psychiatric illness may be seen.

Entities:  

Mesh:

Year:  1995        PMID: 7501785     DOI: 10.1016/S0033-3182(95)71610-3

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  7 in total

1.  Cognitive impairment in progressive supranuclear palsy is associated with tau burden.

Authors:  Shunsuke Koga; Adam Parks; Koji Kasanuki; Monica Sanchez-Contreras; Matthew C Baker; Keith A Josephs; J Eric Ahlskog; Ryan J Uitti; Neill Graff-Radford; Jay A van Gerpen; Zbigniew K Wszolek; Rosa Rademakers; Dennis W Dickson
Journal:  Mov Disord       Date:  2017-10-30       Impact factor: 10.338

2.  Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.

Authors:  Sarah Hewer; Sue Varley; Adam L Boxer; Eldho Paul; David R Williams
Journal:  Mov Disord       Date:  2016-10       Impact factor: 10.338

Review 3.  Current concepts in the pharmacotherapy of pseudobulbar affect.

Authors:  Erik P Pioro
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

4.  Behavioral abnormalities in progressive supranuclear palsy.

Authors:  Adam Gerstenecker; Kevin Duff; Benjamin Mast; Irene Litvan
Journal:  Psychiatry Res       Date:  2013-09-12       Impact factor: 3.222

5.  Psychometric properties of the Beck Depression Inventory-II in progressive supranuclear palsy.

Authors:  Sofia Cuoco; Arianna Cappiello; Filomena Abate; Maria Francesca Tepedino; Roberto Erro; Giampiero Volpe; Maria Teresa Pellecchia; Paolo Barone; Marina Picillo
Journal:  Brain Behav       Date:  2021-09-07       Impact factor: 2.708

6.  Major depressive disorder preceding the onset of progressive supranuclear palsy.

Authors:  Won-Hyoung Kim; Young-Soo Lee; Seung-Ho Jung; Hye-Jin Choi; Myung-Ji Lee; Min-Hee Kang; Chul-Eung Kim; Jeong-Seop Lee; Jae-Nam Bae
Journal:  Psychiatry Investig       Date:  2009-06-30       Impact factor: 2.505

Review 7.  Neuropsychiatric disturbances in atypical parkinsonian disorders.

Authors:  Daniele Belvisi; Isabella Berardelli; Antonio Suppa; Andrea Fabbrini; Massimo Pasquini; Maurizio Pompili; Giovanni Fabbrini
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-09       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.